Recently, metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed. It is uncertain how indices that predict fatty liver are associated with MAFLD in Japanese.
Methods:
Among subjects who underwent a health examination at our hospital, 1257 (men: 787, women: 474) subjects participated in fatty liver evaluation of the fatty liver index (FLI) and fatty liver predicting index (FLPI) were included in this cross-sectional study. The discriminatory ability of each index for MAFLD was tested using receiver operating characteristic curve analysis. The association between FLI, FLPI, and MAFLD was investigated using multiple logistic regression analysis.
Results:
FLI and FLPI had good discriminatory ability for identifying MAFLD in both men and women, with specific cutoff values. Both FLI and FLPI were significantly higher in subjects with MAFLD, and the odds of MAFLD were higher among those in the highest tertile relative to the lowest tertile in both men and women. FLI and FLPI were higher in subjects who met the criteria for both MAFLD and metabolic syndrome (MetS) compared to those who had MAFLD or MetS alone, and most of the examined parameters in subjects with both conditions indicated a high metabolic risk profile.
Conclusions:
The study suggests that FLI and FLPI are valuable tools for predicting MAFLD and are similarly correlated with the disease. Furthermore, the highest values of these indices were observed in subjects who met the criteria for both MAFLD and MetS, emphasizing the importance of considering both conditions when assessing metabolic risk.
Get full access to this article
View all access options for this article.
References
1.
YounossiZ, AnsteeQM, MariettiM, et al.Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018; 15:11–20; doi: 10.1038/nrgastro.2017.109
2.
Yki-JärvinenH. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol, 2014; 2:901–910; doi: 10.1016/S2213-8587(14)70032-4
3.
InoueY, QinB, PotiJ, et al.Epidemiology of obesity in adults: Latest trends. Curr Obes Rep, 2018; 7:276–288; doi: 10.1007/s13679-018-0317-8
4.
ChalasaniN, YounossiZ, LavineJE, et al.The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018; 67:328–357; doi: 10.1002/hep.25762
5.
HuangTD, BeharyJ, ZekryA. Non-alcoholic fatty liver disease (NAFLD): A review of epidemiology, risk factors, diagnosis and management. Intern Med J, 2020; 50:1038–1047; doi: 10.1111/imj.14709
6.
YounossiZ, TackeF, ArreseM, et al.Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2019; 69:2672–2682; doi: 10.1002/hep.30251
7.
EslamM, SanyalAJ, GeorgeJ, et al.MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020; 158:1999–2014.e1; doi: 10.1053/j.gastro.2019.11.312
8.
EslamM, NewsomePN, SarinSK, et al.A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020; 73:202–209; doi: 10.1016/j.jhep.2020.03.039
9.
HashimotoE, TaniaiM, TokushigeK. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol, 2013; 28:64–70; doi: 10.1111/jgh.12271
10.
CasteraL, Friedrich-RustM, LoombaR. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019; 156:1264–1281. e4; doi: 10.1053/j.gastro.2018.12.036
11.
ZhouJH, CaiJJ, SheZG, et al.Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J Gastroenterol, 2019; 25:1307–1326; doi: 10.3748/wjg.v25.i11.1307
BedogniG, BellentaniS, MiglioliL, et al.The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 2006; 6:33; doi: 10.1186/1471-230X-6-33
14.
CiceroA, D'AddatoS, ReggiA, et al.Hepatic steatosis index and lipid accumulation product as middle-term predictors of incident metabolic syndrome in a large population sample: Data from the Brisighella Heart Study. Intern Emerg Med, 2013; 8:265–267; doi: 10.1007/s11739-012-0875-9
15.
KitadeH, ChenG, NiY, et al.Nonalcoholic fatty liver disease and insulin resistance: New insights and potential new treatments. Nutrients, 2017; 9:387; doi: 10.3390/nu9040387
16.
SviklāneL, OlmaneE, DzērveZ, et al.Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol, 2018; 33:270–276; doi: 10.1111/jgh.13814
17.
InabeF, TakahashiE, MoriyamaK, et al.Risk assessment chart for predicting fatty liver in Japanese subjects. Tokai J Exp Clin Med, 2012; 37:94–101.
18.
TakahashiS, TanakaM, HigashiuraY, et al.Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population. Endocr J, 2022; 69:463–471; doi: 10.1507/endocrj.EJ21-0563
19.
MatthewsDR, HoskerJP, RudenskiAS, et al.Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412–419; doi: 10.1007/BF00280883
20.
FarrellGC, ChitturiS, LauGK, et al.Guidelines for the assessment and management of nonalcoholic fatty liver disease in the Asia-Pacific region: Executive summary. J Gastroenterol Hepatol, 2007; 22:775–777; doi: 10.1111/j.1440-1746.2007.05002.x
AlbertiKG, EckelRH, GrundySM, et al.Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009; 120:1640–1645; doi: 10.1161/CIRCULATIONAHA.109.192644
23.
HuangQ, ZouX, WenX, et al.NAFLD or MAFLD: Which has closer association with all-cause and cause-specific mortality? -results from NHANES III. Front Med (Lausanne), 2021; 8:693507; doi: 10.3389/fmed.2021.693507
24.
FuruhashiM, MuranakaA, YudaS, et al.Independent association of fatty liver index with left ventricular diastolic dysfunction in subjects without medication. Am J Cardiol, 2021; 158:139–146; doi: 10.1016/j.amjcard.2021.07.047
25.
ZouB, YeoYH, CheungR, et al.Fatty liver index and development of cardiovascular disease: Findings from the UK biobank. Dig Dis Sci, 2021; 66:2092–2100; doi: 10.1007/s10620-021-06954-y
26.
YangBL, WuWC, FangKC, et al.External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One, 2015; 10:e0120443; doi: 10.1371/journal.pone.0120443
27.
ChenLW, HuangPR, ChienCH, et al.A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease. J Formos Med Assoc, 2020; 119:173–181; doi: 10.1016/j.jfma.2019.03.016
28.
KojimaS, WatanabeN, NumataM, et al.Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. J Gastroenterol, 2003; 38:954–961; doi: 10.1007/s00535-003-1178-8
29.
RohJH, ParkJH, LeeH, et al.A close relationship between non-alcoholic fatty liver disease marker and new-onset hypertension in healthy Korean adults. Korean Circ J, 2020; 50:695–705; doi: 10.4070/kcj.2019.0379
30.
HigashiuraY, FuruhashiM, TanakaM, et al.Elevated fatty liver index is independently associated with new onset of hypertension during a 10-year period in both male and female subjects. J Am Heart Assoc, 2021; 10:e021430; doi: 10.1161/JAHA.121.021430
31.
HigashiuraY, FuruhashiM, TanakaM, et al.High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects. Sci Rep, 2021; 11:12830; doi: 10.1038/s41598-021-92292-y
32.
SeoIH, LeeHS, LeeYJ. Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: Longitudinal findings over 12 years. Cardiovasc Diabetol, 2022; 21:209; doi: 10.1186/s12933-022-01642-1
33.
HuhJH, KimJY, ChoiE, et al.The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One, 2017; 12:e0180951; doi: 10.1371/journal.pone.0180951
34.
TakahashiS, TanakaM, FuruhashiM, et al.Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects. Sci Rep, 2021; 11:8606; doi: 10.1038/s41598-021-88025-w
35.
OlubamwoOO, VirtanenJK, VoutilainenA, et al.Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction. Eur J Gastroenterol Hepatol, 2018; 30:1047–1054; doi: 10.1097/MEG.0000000000001183
36.
ChungGE, JeongSM, ChoEJ, et al.Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study. Metabolism, 2022; 133:155222; doi: 10.1016/j.metabol.2022.155222
37.
MoonJH, KimW, KooBK, et al.Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease. Gut Liver, 2022; 16:433–442; doi: 10.5009/gnl210167
38.
Zelber-SagiS, WebbM, AssyN, et al.Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol, 2013; 19:57–64; doi: 10.3748/wjg.v19.i1.57
39.
AsaturyanHA, BastyN, ThanajM, et al.Improving the accuracy of fatty liver index to reflect liver fat content with predictive regression modelling. PLoS One, 2022; 17:e0273171; doi: 10.1371/journal.pone.0273171
40.
MoriyamaK. Associations between the triglyceride to high-density lipoprotein cholesterol ratio and metabolic syndrome, insulin resistance, and lifestyle habits in healthy Japanese. Metab Syndr Relat Disord, 2020; 18:260–266; doi: 10.1089/met.2019.0123
41.
MoriyamaK, UrataN, MasudaY, et al.Usefulness of triglyceride to high-density lipoprotein ratio and alanine aminotransferase for predicting insulin resistance and metabolic syndrome in the Japanese population. Metab Syndr Relat Disord, 2021; 19:225–232; doi: 10.1089/met.2020.0121
42.
ZhengR, DuZ, WangM, et al.A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis, 2018; 17:262; doi: 10.1186/s12944-018-0913-3
43.
FanN, PengL, XiaZ, et al.Triglycerides to high density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: A cross-sectional study. Lipids Health Dis, 2019; 18:39; doi: 10.1186/s12944-019-0986-7
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
